Pfizer, BioNTech: Vaccine More Than 91% Effective After 6 Months In Study
April 01, 2021 at 10:40 AM EDT
Pfizer Inc. and BioNTech SE announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study, showing the Pfizer-BioNTech COVID-19 vaccine, was 91.3% effective against COVID-19.